Serum neuron-specific enolase (NSE) is considered a tumor marker in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [1]. It is elevated in 30%-50% of GEP-NET patients and correlates with tumor size [2, 3]. NSE has a sensitivity of 38% and specificity of 73% for GEP-NET detection [2]. The prognostic role of serum NSE as a biomarker for GEPNETs patients' survival is poorly studied [4].
ENETS/WHO grade significantly contributed (P < 0.001) to the model, but that NSE remained independently associated with overall survival (P < 0.001). Multivariate analysis data are shown (supplementary Table S1 , available at Annals of Oncology online).
This study demonstrates that NSE is a biomarker for overall survival in ENETS TNM stage IV GEP-NET patients. Our study cohort had a median follow-up of almost 5 years and an mOS of over 8.5 years across all groups. Elevated NSE was found in over 40% of patients, confirming published data [2, 3] . Elevated serum NSE indicates a more aggressive disease course and determination of NSE at first consultation could, therefore, have prognostic implications. Approval was based on the results of the randomized phase III CORRECT trial, which compared regorafenib with placebo and best supportive care in patients who had previously received standard chemotherapies, bevacizumab, and, if they were RAS wild-type, cetuximab and panitumumab [4] . The trial randomized 760 patients to regorafenib or placebo. The median overall survival (OS) was 6.4 months in the regorafenib group versus 5.0 months in the placebo group. The study met the primary end point, with an improvement of 1.4 months in median OS favoring regorafenib [hazard ratio (HR) 0.77; 95% confidence interval (CI) 0.64-0.94].
The recently published cost-effectiveness analysis by Goldstein et al. [5] emphasizes the high incremental cost with low incremental benefit of regorafenib in mCRC. It is an additional example of a novel anticancer drug that provides low value at its current cost and another major challenge for finding new ways of pricing and payment systems [6] . In addition to current strategies, we would suggest to consider NNT for developing a new pricing/ reimbursement strategy for novel biologic agents [7] . The NNT offers a measurement of the impact of a medicine or therapy by estimating the number of patients that need to be treated to prevent one additional adverse outcome. For trials with a binary outcome, the NNT can be obtained as the reciprocal of the absolute difference in proportions of patients with the outcome of interest. In trials using a time-to-event end point, the NNT can be calculated in a similar way, as the reciprocal of the difference between survival probabilities in the active and control treatment groups at a chosen time point. Having the HR and the survival rates, the NNT will be calculated as: NTT = 1/{[Sc(t)]HR − Sc(t)} where Sc(t) is the survival for control group at time 't'. NNTs can be rounded up to the nearest whole number and accompanied by the 95% CI. For example, with an HR = 0.8 and a survival rate of 60% in the control group at 12 months, the NNT will be 1/[(0.6×0.8)-0.6] ≈16 patients [7] . Therefore, 16 patients have to be treated with the experimental drug for one additional patient to survive at that time point.
We evaluated survival data and OS curves reported in the CORRECT trial publication [4], and we estimated a 10.9 NNT and a 10.4 NNT at 6 and 9 months, respectively ( Table 1 ). The observed 6.4 months median OS in the regorafenib group falls between these two time points. As provided in Table 1 , on average 10 patients (95% CI 6-44) are needed to be treated with regorafenib to prevent one additional event (death) compared with placebo. The more recent phase III CONCUR trial of regorafenib monotherapy was conducted in Asia and in a less heavily pretreated patient population [8] . The median OS ( primary end point) was 8.8 months with regorafenib versus 6.3 months with placebo (HR 0.55; . As presented in Table 1 , the NNT in the CONCUR trial at 9 months is 4.6 (95% CI 3-10). Accordingly, on average 5 patients are needed to be treated with regorafenib to prevent one additional event (death) compared with placebo.
Payment of regorafenib for treating mCRC patients in thirdline setting could be negotiated according to the results of the NNT analysis. Assuming the use of regorafenib in Western countries and in patients resembling the CORRECT study population, the negotiation between the pharmaceutical company and a national health care system could be based on cost reductions between 1/6 (lower limit of the 95% CI of the NNT) and 1/10 (the NNT). Alternatively, an 'NNT-based reimbursement plan' could be agreed with the pharmaceutical companies for covering drug expanses of 6 patients at the 7th treated, or 10 patients at the 11th treated. Applying a similar procedure in the setting of Asian patients with characteristics of the CONCUR study population, it would result in a negotiation with cost reduction ranging between 1/3 (lower limit of the 95% CI of the NNT) and 1/5 (the NNT).
Regorafenib has a complex mechanism of action that might never allow identification of biomarkers for patients selection [9] . Therefore, payer coverage determination that address clinical value in addition to statistically significant clinical 
